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ABSTRACT
Chemotherapy resistance frequently drives tumor progression. Increased 
expression of ST8SIA4 has been reported in diverse carcinomas and highly 
correlates with leukemia multidrug resistance (MDR). MicroRNAs (miRNA) are 
widely recognized as key players in cancer progression and drug resistance. Here, 
to explore whether miRNA modulates the sensitivity of chronic myelocytic leukemia 
(CML) to chemotherapeutic agents and regulates ST8SIA4 expression, we analyzed 
the complete miRNA expression profile and found a subset of miRNAs specifically 
dysregulated in adriamycin-resistant CML cell line K562/ADR and its parent cell line 
K562. Compared with three pairs of CML cell lines and 38 clinical samples of peripheral 
blood mononuclear cells (PBMC) of CML patients, miR-181c expression was down-
regulated in drug-resistant cell lines and CML/MDR samples. Altered expression levels 
of miR-181c influenced the MDR phenotypes of K562 and K562/ADR. Reporter-gene 
assay showed that miR-181c directly targeted and inhibited the ST8SIA4 expression, 
as well as miR-181c was inversely correlated with the levels of ST8SIA4 expression in 
CML cell lines and samples. Moreover, ST8SIA4 could reverse the effect of miR-181c 
on drug resistance in K562 and K562/ADR cells in vitro. Upregulation of miR-181c 
sensitized K562/ADR cells to adriamycin in vivo through directly suppressing ST8SIA4 
expression. Further investigation showed that miR-181c mediated the activity of 
phosphoinositide-3 kinase (PI3K)/AKT signal pathway, and inhibition of PI3K/Akt 
in K562 cells counteracted miR-181c-mediated MDR phenotype. These data revealed 
an important role for miR-181c in the regulation of chemoresistance in CML, and 
suggested the potential application of miR-181c in drug resistance treatment.
INTRODUCTION
Chronic myeloid leukemia (CML) is a 
myeloproliferative disorder characterized by BCR-
ABL fusion gene [1]. Over the past two decades, major 
advances have been achieved in the treatment of cancers 
thanks to the highly potent antineoplastic drugs. However, 
chemoresistance is still a significant obstacle for successful 
chemotherapy of CML patients.
MicroRNAs (miRNAs) are a class of regulatory 
non-coding RNAs of 19-25 nucleotides which act 
by targeting specific messenger RNAs (mRNAs) 
for degradation or inhibition of translation through 
base pairing to partially or fully complementary 
sites [2]. It has been demonstrated that miRNA-
mediated gene regulation was involved in multiple 
biological processes, such as cell proliferation, 
migration and invasion, differentiation, survival, and 
tumorigenesis [3]. It has been reported that miRNAs 
play important roles in chemotherapeutic resistance 
[4], highlighting miRNAs as potent therapeutic targets 
or chemoresistant modulators in cancer treatment. 
Ectopic expression of miR-370 sensitized K562 cells 
to homoharringtonine and partially targeted FoxM1 
by inducing apoptosis [5]. Additionally, inhibition 
of miR-21 by antagomiR-21 markedly increased 
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apoptosis induced by imatinib in CML [6], and forced 
expression of miR-217 sensitizes dasatinib-resistant 
K562 cells to dasatinib [7]. More recently, miR-17 and 
miR-20a have been demonstrated to be involved in 
resistance of the leukemia cells to chemotherapeutic 
drug VP-16 mediated by BIM-S [8].
Sialic acids are negatively charged nine-carbon 
carboxylated monosaccharides on glycosylated 
proteins and lipids formed due to post translational 
modification [9]. Most cell surface glycans are highly 
sialylated and often involved in cell-cell and/or cell-
extracellular matrix interaction [10]. High level of 
ST3Gal III sensitizes ovarian cancer cells to Taxo [11]. 
Endogenous expression of ST6GalNAc I in CML cell 
line K562 was associated with the expression of the STn 
O-glycan related to a lack of response to chemotherapy 
[12]. In many tumors, continued activation of 
phosphatidylinositol-3-OH kinase (PI3K)-Akt pathway 
has been implicated as a mechanism of resistance to 
cytotoxic chemotherapy agents [13, 14]. ST8SIA4 
has been reported to enhance the chemoresistance in 
leukemia by phosphorylating and activating of Akt 
at Ser473 and Thr308 specifically and increasing the 
activity of PI3K/AKT signaling pathway [15, 16].
By combining microarray analyses and real-time 
PCR, we found that miR-181c levels remained low in 
K562/ADR cells but became markedly higher in K562 
cells. Other study has reported that upregulation of 
miR-181c contributes to chemoresistance in pancreatic 
cancer. Based on the above, we selected miR-181c for 
analysis. By miRNA target prediction algorithms, and 
experimental validation approaches, the objective of 
this study was to reveal the molecular mechanisms of 
miR-181c in adriamycin-resistant CML cancer.
RESULTS
MiRNA-181c is downregulated in chemoresistant 
CML cell lines and CML/MDR patients
A screen to identify miRNAs involved in adriamycin 
resistance was performed in K562 and K562/ADR cell 
lines, which were made adriamycin-resistant by continuous 
exposure to adriamycin in vitro. We identified 41 miRNAs 
to be dysregulated at least 5-fold in resistant compared to 
adriamycin sensitive parental cells (Table 1). Supervised 
hierarchical clustering using the 41 differentially expressed 
miRNAs clustered cell lines according to miRNA 
expression rather than doxorubicin response (Figure 1A). 
We found that miR-181c levels remained low in K562/
ADR cells but became markedly higher in K562 cells. We 
further confirmed miR-181c expression using real-time 
PCR. As shown in Figure 1B, the expressions of miR-181c 
were decreased in K562/ADR, KU812/ADR, KCL22/ADR 
cells. To identify the expression level of miR-181c in CML 
patients, the PBMC isolated from CML patients was also 
analyzed. The PBMC were first divided into two groups, 
CML without MDR and CML/MDR. The frequency of 
P-gp positivity was 57.9% (22 of 38) in the CML patients. 
As shown in Figure 1C, miR-181c expression was increased 
in CML patients compared with that in CML/MDR patients. 
We hypothesized that miR-181c might functionally regulate 
therapy response. We therefore focused on its role in 
chemoresistance regulation.
Table 1: A Upregulation of miRNAs in K562/ADR cells by miRNA expression arrays
















MiR-181c signature impacts chemoresistance of 
K562 and K562/ADR cells in vitro
The role of miR-181c in chemoresistance was 
characterized by endogenously silencing miR-181c in 
K562 cells. As shown in Figure 2B, transient transfection 
of antagomiR-181c in K562 cell resulted in an increase 
in cell viability to ADR, VCR and Taxol. Moreover, 
increased IC50 values for chemotherapeutic agents were 
observed, after downregulation of miR-181c (Figure 
2C). In addition, flow cytometry analysis showed that 
inhibition of miR-181c led to a decrease in the apoptosis 
rate (Figure 2D). The role of miR-181c in chemoresistance 
was further examined by upregulation of miR-181c. K562/
ADR cells were transiently transfected with miR-181c or 
mimic control. Quantitative RT-PCR confirmed that the 
transient transfection of miR-181c effectively enhanced 
the expression of miR-181c (Figure 3A). Conversely, 
transient transfection of miR-181c resulted in a significant 
decrease in cell viability of K562/ADR cells to ADR, 
VCR and Taxol (Figure 2B). Furthermore, overexpression 
of miR-181c sensitized cells to chemotherapy, as 
indicated by a decrease in the IC50 (Figure 3C). 
Moreover, flow cytometry analysis confirmed that miR-
181c significantly increased the apoptosis of these cancer 
cells upon drug treatments (Figure 3D). Collectively, 
these results indicated that downregulation of miR-181c 
promotes chronic myelocytic leukemia cell resistance to 
chemotherapeutic drugs in vitro.
ST8SIA4 is a target of miR-181c in CML cells
To investigate the molecular mechanisms of how 
miR-181c decreases chemoresistance resistance, several 
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well-developed miRNA algorithms were employed, such 
as TargetScan, PicTar, and miRNA.org, to obtain possible 
mRNA targets of miR-181c. ABI1, ACSL1, APOO, BRAP, 
BRD1, PLEK,SETX, RLF,ST8SIA4, DHX57, DOCK7, 
ENPP1, FOS et al were among the potential targets. 
Polysialylation of NCAM is implemented by the two 
polysialyltransferases (polySTs) ST8SIA2 and ST8SIA4. 
Recently, the phosphatidylinositol-3-kinase (PI3K) also 
has been implicated in the signalling events initiated by 
NCAM [15]. ST8SIA4 seems to be the major polyST of 
the adult brain [16]. Moreover, constitutive activation of 
PI3K/Akt is associated with the expression of ST8SIA4 
[17,18]. In addition, our previous study has demonstrated 
it was involved in the development of multidrug resistance 
in human leukemia [19, 20]. So, among the search results, 
ST8SIA4 captured our attention.
Then, we investigated whether ST8SIA4 was a target 
of miR-181c in CML cells. Luciferase reporter constructs 
were made, containing the putative binding sites of 
ST8SIA4-wt-3’UTR(222-243) regions, ST8SIA4-wt1-
3’UTR(2117-2140) regions or the mutant 3’-UTR regions 
(mut:ST8SIA4-mut-3’UTR(222-243), mut1:ST8SIA4-wt1-
3’UTR(2117-2140)) of these transcripts within miR-181c–
binding seed regions.
Forced miR-181c expression decreased luciferase 
activity, and this suppression was reversed by the mutation 
of the target sequences in the 3’-UTR of ST8SIA4 
(Figure 4A). Western blotting analysis showed that the 
inhibition of miR-181c increased ST8SIA4 expression 
levels in K562 cells. Whereas, ectopic expression of 
miR-181c by transient transfection decreased the protein 
expression of ST8SIA4 in K562/ADR cells (Figure 4B). 
Furthermore, analysis of miR-181c and ST8SIA4 expression 
in CML patients by Spearman’s correlation analysis showed 
a significant inverse correlation (r= –0.7355, P =0.000; 
Figure 4C) Taken together, the results indicated that miR-
181c targets ST8SIA4 to repress its expression by binding 
to 3’-UTR regions.
Figure 1: Expression of miR-181c is associated with chemoresistance in chronic myelocytic leukemia. A. Comparison of 
miRNA expression in K562/ADR and its parental cells by using the Exiqon Human miRNA microarray. Expression levels of miR-181c 
in K562 cells were higher than those in K562/ADR cells. B. A validation experiment was carried out using qRT-PCR. The relative levels 
were normalized to U6 snRNA. Expressions of miR-181c in parental K562, KCL22 and KU812 cells were higher compared to their ADR-
resistant cells (*p<0.05). C. Moreover, chemoresistant cancer samples have significantly lower levels of miR-181c (*p<0.05).
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ST8SIA4 reverses the effect of miR-181c-
mediated chemoresistance in K562 and K562/
ADR cells
To assess the possible role of ST8SIA4 in the 
chemoresistance-mediating capability of miR-181c, 
we performed functional loss assays by co-transfecting 
ST8SIA4-shRNA plasmid and antagomiR-181c in K562 
cells. Western blotting analyses showed a decrease 
of ST8SIA4 protein in antagomiR-181 transfected 
clone (K562-antagomiR-181c) (Figure 5A), indicating 
the effective inhibition of the wild-type protein. 
While suppression of miR-181c expression promoted 
chemoresistance, knockdown of ST8SIA4 reversed 
antagomiR-181c-mediated sensitivity of the K562 cells 
to ADR, VCR and Taxol (Figure 5B). Re-introducing 
the wild-type form of ST8SIA4 in K562/ADR cells led 
to a marked increase in the protein expression upon 
transfection with the miR-181c compared to control 
(Figure 5C). As shown in Figure 5D, while miR-181c 
expression induced inhibitory effects on chemoresistance, 
recombinantly expressed ST8SIA4 reversed miR-
181c-mediated sensitivity of K562/ADR cells to drug 
treatment (Figure 5D). Equally important, knockdown of 
ST8SIA4 copied the phenotype of high miR-181c levels 
by sensitizing cells to chemotherapeutic agents [19]. 
These results suggested that ST8SIA4 is responsible for 
mediating the effects of miR-181c on chemoresistance in 
CML cell lines.
MiR-181c regulates chemoresistance via 
ST8SIA4 dependent PI3K/AKT signaling 
pathway
It has been reported that inhibition of PI3K/AKT 
signaling has proven to be an efficient way to attenuate 
the resistance of chemotherapy [36]. Our previous results 
showed that PI3K/AKT pathway is activated in K562/
ADR cells compared with its parental cells K562, and 
ST8SIA4 was positive regulators of PI3K/AKT pathway. 
In present study, given that the expression of ST8SIA4 
was down-regulated by miR-181c in CML cells (Figure 4), 
we further investigated whether dysregulation miR-181c 
altered the activation of PI3K/AKT pathway. As shown in 
Figure 6A, a significant increase in PI3K p110α, phospho-
Akt 308, phospho-Akt 473 and NF-κB protein was 
observed when miR-181c was inhibited in K562 cells. By 
contrast, there was no change in the total amount of Akt 
protein, demonstrating a truedecrease in phosphorylation 
status. In addition, after overexpression of miR-181c in 
Figure 2: Knockdown of miR-181c promotes drug resistance in vitro. A. qRT-PCR was performed to measure miR-181c levels 
in K562 cells transfected with the antagomir control or antagomiR-181c. Decreased miR-181c levels were observed in the antagomiR-
181-transfected cells compared to the control (*p<0.05). B. K562 cells were treated with ADR, VCR and Taxol for 48 h. Cell viability 
was determined using a CCK8 assay. More cells survived in antagomiR-181c-transfected group (*p<0.05). C. Knockdown of miR-181c 
increased IC50 values of K562 cells to ADR, VCR, and Taxol (*p<0.05). D. K562 cells were treated with ADR, VCR and Taxol, followed 
by analysis of apoptosis. There were fewer cells undergoing apoptosis in the antagomiR-181-transfected group (*p<0.05).
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Figure 3: Upregulation of miR-181c decreases cell chemoresistance in vitro. A. qRT-PCR was performed to measure miR-181c 
levels in K562/ADR cells transfected with the mimic control or miR-181c. Increased miR-181c levels were observed in the miR-181-
transfected cells compared to the control (*p<0.05). B. K562/ADR cells were treated with ADR, VCR and Taxol for 48 h. Cell viability 
was determined using a CCK8 assay. Lower cells survived in miR-181c-transfected group (*p<0.05). C. Ectopic expression of miR-181c 
sensitized K562/ADR cells to ADR, VCR and Taxol (*p<0.05). D. K562/ADR cells were treated with ADR, VCR and Taxol, followed by 
analysis of apoptosis. There were more cells undergoing apoptosis in the miR-181c-transfected group (*p<0.05).
Figure 4: ST8SIA4 is targeted by miR-181c. A. Predicted miR-181c target sequence in 3′UTRs of ST8SIA4 at two different sites. 
293T cells were co-transfected with miR-181c or the control and luciferase reporter constructs or the mutants. MiR-181c repressed the 
activity of ST8SIA4-wt-3’UTR and ST8SIA4-wt1-3’UTR but had no effect on that of ST8SIA4-mut-3’UTR and ST8SIA4-mut1-3’UTR 
(*p<0.05). wt:ST8SIA4-wt-3’UTR(222-243), mut:ST8SIA4-mut-3’UTR(222-243), wt1:ST8SIA4-wt1-3’UTR(2117-2140), mut1:ST8SIA4- 
mut1-3’UTR(2117-2140). B. Western blotting of ST8SIA4 expression. GAPDH served as the loading control. C. The correlation between 
miR-181c and ST8SIA4 expression levels in CML/MDR (N = 22) and CML patients (N = 16)
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K562/ADR cells, we observed a noticeable decrease in 
protein expression of PI3K110α, p-Akt 308, p-Akt 473 
and NF-κB (Figure 6B). Together, the data confirmed that 
augmented PI3K/AKT pathway expression accompanying 
miR-181c deficiency was also associated with activation 
of PI3K/AKT.
To further support the role of PI3K/AKT signaling 
in regulation chemoresistance by miR-181c, Akt shRNA 
was utilized in K562 cells. The protein levels of the 
main signal molecules of PI3K/AKT pathway were 
analyzed by western blotting. Our results indicated 
that in K562-antagomiR-181c cells, the protein levels 
of PI3K/AKT pathway were decreased in Akt shRNA 
treatment group compared to control group (Figure 6C). 
In addition, inhibition of PI3K/AKT pathway made the 
K562-antagomiR-181c cells susceptible to chemotherapy 
(Figure 6D). These data indicated the involvement PI3K/
AKT pathway in suppression of drug resistance by 
miR-181c.
MiR-181c decreases chemoresistance of K562/
ADR cells in vivo
The promotive effect of miR-181c on CML cell 
chemoresistance was further examined in vivo. Mice 
were inoculated subcutaneously (1 × 107 K562/ADR 
cells per mouse) in the right flank. One week later, the 
mice were randomly divided into four groups (n = 6/
group, mimic control group, mimic control+ADR group, 
miR-181c group, miR-181c+ADR group). Mice were 
intratumorally injected with mimic control or miR-181c 
mimic three times per week for three weeks,combining 
with intraperitoneal injection of adriamycin (7mg/kg) 
weekly or PBS. The tumor volumes were decreased in 
the miR-181c group,as compared to the mimic control 
group (Figure 7A). Significantly, the combined miR-181c 
and adriamycin treatment markedly restricted the tumor 
growth to low volumes. These results suggested that miR-
181c decreased adriamycin resistance and tumor growth, 
while injection of miR-181c sensitized K562/ADR cells 
to adriamycin treatment and inhibited tumor growth. 
Meanwhile, tumors injected with miR-181c had decreased 
Ki67, ST8SIA4, PI3K p110α, p-Akt 308, p-Akt 473 and 
NF-κB expression, analyzed by immunohistochemistry 
(Figure 7B and 7C). These results further suggest that 
miR-181c and its downstream PI3K/AKT pathway play 
important roles in controlling K562/ADR cells adriamycin 
sensitivity in vivo.
DISCUSSION
MiRNAs can regulate various biological processes 
in tumorigenesis, metastasis and chemoresistance. In the 
current study, we reported that specific miRNA expression 
signatures characterized and contributed to the MDR 
phenotypic of CML cell lines. Among them, we validated 
miR-181c, which was downregulated in chemoresistant 
CML cell lines and CML/MDR patients. Furthermore, 
miR-181c could exert chemoresistant functions and 
impede CML drug resistance, partly through targeting 
Figure 5: The silence or overexpression of ST8SIA4 reversed the effect of miR-181c on drug resistance. A, C. Western 
blotting analysis of the protein levels of ST8SIA4 in cells transfected with specific ST8SIA4-shRNA or ST8SIA4, respectively. (B) ST8SIA4 
silencing reversed the drug resistance caused by the downregulation of miR-181c in K562 cells (*p<0.05). D. Re-expression of ST8SIA4 
could antagonize miR-181c mediated chemo-sensitivity in K562/ADR cells (*p<0.05).
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ST8SIA4 and its downstream PI3K/AKT pathway both 
in vitro and in vivo. Our data provide a insight into the 
function of miR-181c in regulating ST8SIA4 and drug 
resistance in CML cells.
The miR-181 family contains four miRNAs 
(miR-181a/b/c/d). Recent studies showed that 
miR-181 also play a vital role in chemotherapeutic 
resistance. Restoration of miR-181a expression could 
sensitize K562/A02 and HL-60/Ara-C cell lines to 
chemotherapeutic agents [21, 22]. MiR-181b enhanced 
resistance to the anticancer drug doxorubicin in 
hepatocellular carcinoma (HCC) [23], and functioned as 
a tumor suppressor in AML chemoresistance [24]. In the 
present study, we performed miRNA expression profiling 
in adriamycin-sensitive cell line K562 and adriamycin-
resistant cell line K562/ADR. The expression of miR-
181c was decreased in ADR-resistant cell lines (K562/
ADR, KU812/ADR, KCL22/ADR) as well as in CML/
MDR patients. Moreover, we found that inhibition of 
miR-181c may enhance resistance to the anticancer 
drugs of K562 cells. Overexpression of miR-181c 
sensitized K562/ADR cells to chemotherapy both 
in vitro and in vivo. Our findings were supported by 
investigations in another study. Contrary to our results, 
miR-181c contributed pancreatic cancer cell resistance 
to chemotherapeutic drugs by inactivating the Hippo 
signaling pathway [25]. Down-regulation of miR-181c 
was found in imatinib-resistant CML patients, compared 
with imatinib-responders patients [26], which was 
consistent with our study. These results additionally 
demonstrate that miR-181c may be a reasonable approach 
to improving or prolonging drug sensitivity in CML.
Altered mRNA expression levels of 
sialyltransferases in different cancers are reported as 
potential targets for therapeuticapproaches [11, 27-29]. 
Sialyltransferases of the mammalian ST8SIA family 
Figure 6: Downregulation of miR-181c activated PI3K/AKT signaling. A, B. Western blotting analysis of PI3K p110α, 
phosphorylated Akt (p-Akt 308), phosphorylated Akt (p-Akt 473), total Akt, and NF-κB protein levels in indicated cells. GAPDH was used 
as a loading control. C. Expression of PI3K/Akt signaling molecules were examined by western blot analysis, treated with Akt shRNA in 
K562/antagomiR-181c cells. D. Inactivation of PI3K/Akt signaling using Akt-shRNA significantly increased the chemo-sensitivity of K562 
cells transfected with antagomiR-181c, analyzed by CCK-8 assay (*p<0.05).
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catalyze oligo- and polysialylation of surface-localized 
glycoproteins and glycolipids through transfer of 
sialic acids from CMP-sialic acid to the nonreducing 
ends of sialic acid acceptors [30]. Our previously 
showed that the sialyltransferase ST8SIA4, encoded 
N-acetylgalactosaminide a-2, 8-sialyltransferase IV 
(ST8SIA4), was critical for CML multidrug resistance 
[19, 20]. In addition, miRNAs that target glycosylation 
enzymes have been identified. Vaiana et al demonstrated 
that MGAT4A, an N-acetylglucosamintltransferase that 
installed the β-1, 4 branch of N-glycans, was directly 
regulated by miR-424 in multiple mammary epithelial 
cell lines [31]. MiR-200a might target ST3GAL3 and 
ST3GAL4 sialyltransferases, which potentially involved 
in antithrombin sialylation, were 85% lower in neonates 
in comparison with adults [32]. MiR-199a targeted 
ST6GAL1 and reduced both the sialylation and the protein 
level of Necl-2 [33]. Herein we demonstrated that miR-
181c targets the 3’ UTR of the sialylation related gene 
ST8SIA4, suggesting the enzyme may play a role in 
cancer chemoresistance. Thus, further exploration of the 
interaction between miR-181c and ST8SIA4 in alternate 
MDR system of CML was warranted. We showed that 
downregulation of miR-181 contributes to high levels of 
ST8SIA4. While, forced expression of miR-181c resulted 
in a significant decrease of ST8SIA4. We also observed 
a significant inverse correlation between miR-181c and 
ST8SIA4 levels in CML patients. Furthermore, silencing 
of the ST8SIA4 gene reversed antagomiR-181c-mediated 
sensitivity of the K562 cells to ADR, VCR and Taxol. 
Overexpression of ST8SIA4 in K562/ADR cells increased 
chemoresistance after miR-181c introduction. Taken 
together, our findings suggest that miR-181c mediates 
CML chemoresistance at least in part by functionally 
targeting ST8SIA4.
Numerous studies have demonstrated that activation 
of the PI3K/Akt signaling pathway was essential to the 
development and progression of most cancer types 
and associated with nearly all aspects of the malignant 
phenotype of cancer, such as uncontrolled proliferation, 
resistance to cell death, invasiveness, angiogenesis and 
metastasis [34, 35]. PI3K/AKT inhibition correlated 
down-regulation of NF-kappaB activity and inhibition 
P-gp function in murine lymphoma cell lines [36]. 
Inhibition of the PI3K/mTOR pathway was a promising 
therapeutic approach in patients with acute lymphoblastic 
leukemia [37]. Recent evidences have indicated that 
miRNAs were involved in the regulation of PI3K/AKT 
signaling pathways. For example, overexpression of 
miR-22 in CLL B cells switched on PI3K/AKT, leading 
to downregulation of p27 (-Kip1) and overexpression of 
Survivin and Ki-67 proteins [38]. Ectopic expression of 
miR-206 mimics inhibited cisplatin resistance, decreased 
the migration and invasion in cisplatin-resistant lung 
adenocarcinoma cells, partly due to inactivation of MET/
PI3K/AKT/mTOR signaling pathway [39]. Our recent 
study showed that downregulation of ST8SIA4 expression 
suppressed the activity of PI3K/AKT pathway. In the 
Figure 7: MiR-181c sensitizes K562/ADR cells to chemotherapeutic drugs in vivo. A. Tumor volumes of tumors in the mimic 
control, mimic control + ADR, miR-181c and miR-181c+ADR groups were measured on indicated days. Data presented are the mean ± SD 
B, C. Expression levels of Ki67, ST8SIA4 and PI3K/Akt signaling molecules in K562/ADR-mimic control group and K562/ADR-miR-
181c group were analyzed by immunohistochemistry (*p<0.05).
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present study, we found miR-181c-ST8SIA4 axis regualted 
PI3K/AKT in CML cell lines. MiR-181c inhibitor 
enhanced phosphorylation of PI3K/AKT in K562 cells. 
In contrast, miR-181c suppressed the phosphorylation 
of PI3K/AKT in K562/ADR cells. Further investigation 
detected Akt shRNA inhibited the phosphorylation of 
PI3K/AKT in K562-antagomiR-181c cells, subsequently 
leading to a decrease in chemoresistance. Other studies 
also reported that ectopic expression of miR-181a leads 
to AKT phosphorylation, enhancing cell proliferation 
and inducing cell resistance to chemotherapy in T-cell 
leukemia/lymphoma [40]. These findings may indicate 
that miR-181 functions as both an oncomir and tumor-
suppressive miRNA, depending on the tumor type and the 
subtypes of miR-181. These results provides a possible 
mechanism linking miR-181c, PI3K/AKT pathway, 
drug resistance, by which altered expression of ST8SIA4 
leads to drug resistance in CML cell lines. In addition, 
we also assessed the anti-tumor effect of miR-181c in an 
adriamycin-resistant in vivo mice model. We found that 
overexpression of miR-181c enhanced the K562/ADR 
cell sensitivity to adriamycin and inhibited the PI3K/
AKT pathway and ST8SIA4 expression in vivo. Therefore, 
these results further demonstrated in vivo that miR-
181c inhibiting ST8SIA4 and its downstream PI3K/AKT 
pathways is one potential mechanism to overcome drug 
resistance in CML.
In conclusion, our study demonstrated that miR-
181c was downregulated in adriamycin-resistant chronic 
myelocytic leukemia cell lines and CML/MDR patients. 
In addition, we showed that miR-181c regulated 
chemoresistance both in vitro and in vivo by targeting 
ST8SIA4 and mediating its downstream PI3K/AKT. 
Therefore, activation of miR-181c or inactivation of its 
target gene pathway may be a potential strategy to reverse 
drug resistance in human CML.
MATERIALS AND METHODS
Cell culture
Human CML in blast crisis cell lines, K562, KCL22, 
KU812 were both cultured in RPMI 1640 medium (Gibco, 
Grand Island, NY) supplemented with 10% fetal bovine serum 
(Gibco, Grand Island, NY) and 1% penicillin-streptomycin 
(Gibco, Grand Island, NY) at 37°C in humidified atmosphere 
containing 5% CO2. The resistant cell lines, K562/ADR, 
KCL22/ADR, and KU812/ADR were incubated in the 
presence of adriamycin (Sigma, St Louis, MO, 1 μg/ml) until 
at least 3 days before starting the experiments.
Primary patient samples
Thirty-eight previously untreated CML patients were 
included in this study. All patients were diagnosed with 
CML from 2013 to 2015 at First Affiliated Hospital of 
Dalian Medical University (Dalian, China) according to the 
current World Health Organization criteria. The diagnosis 
of CML was based on cytomorphology, cytochemistry, 
multiparameter flow cytometry, immunology, molecular 
genetics and cytogenetics. All the participants were 
provided written informed consent and the study were 
approved by and the institutional ethics committees. 
Peripheral blood mononuclear cells (PBMC) were isolated 
using Ficoll-Hypaque and were further cultured in plastic 
dishes to remove adherent cells at 37°C for 24 h. The 
PBMC were divided into two groups, CML without MDR 
and CML/MDR. The frequency of P-gp positivity was 
57.9% (22 of 38) in the CML patients.The clinical data of 
enrolled 38 patients was given in Supplementary Table S1.
miRNA expression arrays
miRNA arrays were performed for K562 group and 
K562/ADR group (n=3/group) by Exiqon (KangChen, 
China) using the miRCURY™Hy3™/Hy5™ power 
labelling kit and the miRCURY™ LNA Array (v.10.0; 757 
human miRs). The expression values are log2 (Hy3/Hy5) 
ratios. Unsupervised hierarchical clustering of miRNAs 
was performed.
RNA extraction and real-time PCR
Total RNAs for array analysis were extracted using 
Trizol (Invitrogen) and RNAeasy mini kit (Qiagen) or 
RNA was precipitated with isopropanol and glycogen 
(Invitrogen) according to the manufacturer’s instructions. 
cDNA were synthesised from RNA using a TaqMan 
miRNA reverse transcription kit (Applied Biosystems, 
Foster City, CA, USA), and quantified the expression levels 
of miR-181c using a miRNA-specific TaqMan MiRNA 
Assay Kit (Applied Biosystems). The expression of miRNA 
was defined based on the Ct, and relative expression levels 
were calculated as 2-[(Ct of miR-181c) − (Ct of U6)] after normalization 
with reference to expression of U6 small nuclear RNA.
Western blotting
Cells were harvested, lysed and sonicated in RIPA 
buffer. A total of 10-50 μg of protein was electrophoresed 
in SDS-PAGE gels and transferred to polyvinylidene 
difluoride membranes (Millipore, Bedford, MA, USA). 
The membranes were then incubated with the following 
antibodies: anti-ST8SIA4, anti-PI3K p110α, anti-phospho-
Akt 308, anti-phospho-Akt 473, and anti-Akt and anti-NF-κB 
antibodies (Abgent, Cambridge, UK). The immunoblots were 
visualized using an enhanced chemiluminescence detection 
system (Amersham Biosciences, Buckinghamshire, UK).
Cell viability assay
The cell viability was monitored using the Cell 
Counting Kit-8 (CCK8) (Dojindo Molecular Technologies, 
Oncotarget60084www.impactjournals.com/oncotarget
Kumamoto, Japan) according to the manufacturer’s 
protocol. Briefly, cells (1×104) were plated in 96-well plate 
and allowed to grow for 48 h before the addition of CCK8. 
The spectrometric absorbance was measured at 490nm by 
microplate reader (Model 680; Bio-Rad, Hercules, CA, 
USA). All of the experiments were repeated at least three 
times.
Apoptosis assay
Cell apoptosis was evaluated using an Annexin-V-
FITC apoptosis detection kit (BD, Franklin Lakes, NJ, USA). 
Briefly, after treatment with chemotherapeutic agents (K562/
ADR, ADR/VCR/Taxol 40 μg/ml; K562, ADR/VCR/Taxol 
1μg/ml), for 48 h, 2×105 cells were harvested, resuspended 
in 100 μl flow cytometry binding buffer, and stained with 
5 μl Annexin V/FITC followed by 1 μl PI. Cells were then 
incubated in the dark for 15 min at room temperature, and 
400 μl binding buffer was added. The cells were immediately 
measured by FACSCalibur (Becton-Dickinson, CA, USA).
Plasmids, oligonucleotides, shRNA and 
transfection
The region of the human ST8SIA4 3′-UTR, 
generated by PCR amplification from DNA, was cloned 
into vector pmirGLO (Promega). MiR-181c mimic, 
antagomiR-181c from RiboBio (Guangzhou, China). 
For depletion of ST8SIA4, shRNAs were synthesized 
and purified. Overexpressing of ST8SIA4 was generated 
by transduction using a pEGFP-N2 vector (Invitrogen, 
Carlsbad, CA). Transfection was performed using the 
Lipofectamine 2000 reagent (Invitrogen), according to the 
manufacturer’s instruction.
Reporter gene assay
The pmirGLO-ST8SIA4 3’-untranslated region 
(UTR) luciferase-reporter (containg Firefly luciferase 
reporter gene and humanized Renilla luciferase) 
(Promega, Madison, WI, USA) containing many copies 
of the miR-181c binding motif was co-transfected with 
miR-181c mimics or mimic control into HEK 293T cells 
using Lipofectamine 2000 (Invitrogen). Luciferase and 
Renilla signals were measured 48 h after transfection 
using a Dual-Luciferase® Reporter Assay Kit (Promega) 
according to the manufacturer’s protocol.
Xenografted tumor model
Nude mice (4 weeks old) were purchased from the 
Animal Facility of Dalian Medical University Animal 
Facility of Dalian Medical University and housed in 
barrier facilities on a 12-h light/dark cycle. The mice were 
randomly assigned to groups (n = 6/group). The mice 
in groups were inoculated subcutaneously with K562/
ADR cells (1×107) in the right flank, and one week later, 
injected intratumorally with miR-181c mimic or mimic 
control three times per week for 3 weeks, combining with 
intraperitoneal injection of doxorubicin (7mg/kg) weekly. 
Tumors were examined every 7 days. Tumor volume was 
calculated using the equation (length × width2)/2.
Immunohistochemistry
At the end of observation animals were sacrificed 
and tumors were retrieved for further analysis. Tumors 
were immediately immersed in 4% buffered formaldehyde, 
washed, dehydrated, and finally embedded in paraffin. Tumor 
slices 5 μm thick were deparaffinized. After washing steps, 
peroxidase blocking was carried out for 10 min to quench the 
endogenous peroxidase. Tumors were again washed and then 
incubated with the primary antibodies at 4°C overnight. The 
secondary streptavidin-horseradish peroxidase-conjugated 
antibody staining (Santa Cruz Biotech, Santa Cruz, CA) was 
performed at room temperature for 60 min. Subsequently, 
slides were counterstained with hematoxylin.
Statistical analysis
The statistical analyses were performed using SPSS 
software. The data are presented as the mean± SD. Student’s 
t-test (two-tailed) was employed to analyze the significance 
of differences between two groups of data in all pertinent 
experiments. The one-way analysis of variance (ANOVA) 
was used to determine whether there are any significant 
differences between the means of more than two groups. 
The association between miR-181c and ST8SIA4 expression 
was evaluated using Spearman’s correlation analysis. 
Statistical significance was defined as p< 0.05.
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